A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine
Author:
Open Access
- 29 June 2015
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 12 (9) , 1565-1577
Abstract
AVP-825, formerly 'OptiNose Sumatriptan,' is an investigational Breath-Powered(TM) Bi-Directional(TM) intranasal delivery system containing low-dose sumatriptan (22 mg intranasal powder) that avoids limitations of other types of intranasal administration by taking advantage of unique features of nasal anatomy and physiology. This review summarizes intranasal drug delivery for migraine, how the breath-powered technology works, and AVP-825 pharmacokinetic, efficacy and safety/tolerability findings. To identify AVP-825 clinical studies, a PubMed/MEDLINE database search was conducted with the terms AVP-825, OptiNose, OptiNose Sumatriptan, Breath-Powered Nasal Delivery or sumatriptan powder. Of 20 articles, 5 clinical studies were identified, including the head-to-head comparative COMPASS trial (AVP-825 vs oral sumatriptan) and two placebo-controlled studies. AVP-825 has faster sumatriptan absorption versus oral tablets or traditional liquid nasal spray. In Phase II/III randomized, double-blind, placebo-controlled trials, AVP-825 produced early and sustained efficacy with minimal triptan-related adverse effects. In COMPASS, AVP-825 produced earlier reduction of migraine pain intensity and migraine-associated symptoms than 100 mg oral sumatriptan, and higher early rates of pain relief and pain freedom, similar sustained efficacy, and fewer atypical sensations. AVP-825 has the potential to provide migraine patients with improved intranasal administration of sumatriptan that may enhance efficacy and tolerability.Keywords
This publication has 44 references indexed in Scilit:
- Breath Powered Nasal Delivery: A New Route to Rapid Headache ReliefHeadache: The Journal of Head and Face Pain, 2013
- Improved Pharmacokinetics of Sumatriptan With B reath P owered™ Nasal Delivery of Sumatriptan PowderHeadache: The Journal of Head and Face Pain, 2013
- Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with MigraineDrugs, 2013
- Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled studyCephalalgia, 2013
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Nasal drug delivery devices: characteristics and performance in a clinical perspective—a reviewDrug Delivery and Translational Research, 2012
- Acute Treatment of MigrainesCNS Drugs, 2012
- Triptans for the Management of MigraineDrugs, 2010
- Newer Formulations of the TriptansDrugs, 2003
- Clinical Pharmacokinetics of Intranasal SumatriptanClinical Pharmacokinetics, 2002